OpGen, which provides genetic tests that identify multi-drug resistant bacterial infections, raised $17 million by offering 2.85 million units at $6, the midpoint of the downwardly revised range of $5.50 to $6.50. Each unit represents one common share and one warrant to purchase an additional share at 110% of the IPO price. OpGen plans to list on the NASDAQ under the symbol OPGN for its common shares and OPGNW for its warrants. OpGen initially filed confidentially on 11/24/2014. Maxim Group LLC acted as a lead manager on the deal.
